Chemotherapy-Induced Anemia Market Forecast 2024-2033 - Major Trends, Segments And Fastest Growing Regions | Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc

"The chemotherapy-induced anemia market size has grown strongly in recent years. It will grow from $2.4 billion in 2023 to $2.6 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased prevalence of cancer and chemotherapy treatments, aging population leading to higher cancer incidence, expansion of chemotherapy drugs and regimens, improvement in overall cancer survival rates, awareness and diagnosis of anemia as a side effect.

The chemotherapy-induced anemia market size is expected to see strong growth in the next few years. It will grow to $3.46 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to development of supportive care in oncology, rise in healthcare expenditure and infrastructure, personalized medicine and targeted cancer therapies, integration of biomarker-driven treatment approaches, increasing focus on early detection and intervention, integration of digital health technologies in patient management. Major trends in the forecast period include innovation of novel chemotherapy agents, integration of ml, advancements in cancer research and treatment protocols, integration of ai, collaboration between pharmaceutical companies and healthcare providers.

Market Overview -
Chemotherapy-induced anemia (CIA) is a consequence that results from inflammation-induced functional iron deficiency, bone marrow infiltration with disruption of erythropoiesis, and malignant invasion of normal tissue, all of which cause blood loss.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12513&type=smp

Rising Cancer And Anemia Cases Propel Growth In Chemotherapy-Induced Anemia Market
The high prevalence of cancer and anemia is expected to propel the growth of the chemotherapy-induced anemia market going forward. Cancer is a disease where somebody's cells grow out of control and spread to other body regions. In cancer patients receiving aggressive chemotherapy, whether with or without radiation therapy, cancer and chemotherapy-induced anemia (CIA) are frequent occurrences. The medication stimulates the production of red blood cells in the bone marrow and can be used to treat chemotherapy-induced anemia. For instance, in 2023, according to Cancer Research UK, a UK-based independent cancer research organization, the incidence of head and neck cancer in the UK is projected to rise by 3% between 2023 and 2025, while deaths due to head and neck cancers are expected to increase by 12% between 2023 and 2025. Therefore, the high prevalence of cancer and anemia drives the growth of the chemotherapy-induced anemia market.

Competitive Landscape -
Major companies operating in the chemotherapy-induced anemia market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Fresenius Kabi AG, Hospira Inc., Dr. Reddy's Laboratories Ltd., Biocon Ltd., 3SBio Group, FibroGen Inc., Karger AG, Avesthagen Ltd., Blausen Medical Communications Inc., Aileron Therapeutics Inc.

Innovative Therapy For Extensive-Stage Small Cell Lung Cancer
Major companies in the chemotherapy-induced anemia market are focused on developing innovative therapy, such as myeloprotection therapy, for extensive-stage small cell lung cancer and to gain a competitive edge in the market. Myeloprotection therapy is a medical approach aimed at safeguarding bone marrow from damage caused by chemotherapy, reducing associated complications. For instance, in February 2021, G1 Therapeutics Inc., a US-based biopharmaceutical company, received FDA approval for COSELA (trilaciclib), the first myeloprotection therapy designed to reduce chemotherapy-induced myelosuppression, a condition characterized by a reduction in blood cell production in the bone marrow, and it can lead to complications such as neutropenia, anemia, and thrombocytopenia in patients with extensive-stage small-cell lung cancer. Administered before chemotherapy, COSELA protects bone marrow, reducing severe neutropenia incidence and duration. It offers multilineage protection, impacting anemia and the need for rescue interventions.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Key Segments -
The chemotherapy-induced anemia market covered in this report is segmented -
1) By Anemia: Mild Anemia, Moderate Anemia, Severe Anemia, Life-Threatening Anemia
2) By Treatment Type: RBC (Red Blood Cells) Transfusion, Erythropoiesis-Stimulating Agents (ESAs), Iron Supplementation
3) By End-User: Hospitals, Ambulatory Surgical Centers, Multispecialty Clinics, Cancer Research Centers,Cancer Rehabilitation Centers

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.